Table 1.
Patients information in the pan-cancer analysis for cancer immunotherapy
| Patients characteristics | Group | Patients number (%) | P value for OS comparison | P value for TMB comparison |
|---|---|---|---|---|
| ARID1A mutation | ||||
| mutated type | 192 (12) | 0.01 | <0.0001 | |
| wild type | 1468 (88) | |||
| ARID1B mutation | ||||
| mutated type | 85 (5) | 0.0097 | <0.0001 | |
| wild type | 1575 (95) | |||
| ARID2 mutation | ||||
| mutated type | 103 (6) | 0.0054 | <0.0001 | |
| wild type | 1557 (94) | |||
| ARID5B mutation | ||||
| mutated type | 44 (3) | 0.1367 | <0.0001 | |
| wild type | 1616 (97) | |||
| Age | ||||
| ≥ 65 | 738 (44) | 0.8444 | 0.0008 | |
| < 65 | 922 (56) | |||
| Sex | ||||
| male | 1033 (62) | 0.1416 | 0.0603 | |
| female | 627 (38) | |||
| TMB score | ||||
| ≥ 50th percentage | 823 (50) | <0.0001 | NA | |
| < 50th percentage | 837 (50) | |||
| Metastasis | ||||
| metastasis | 900 (54) | 0.1713 | 0.1729 | |
| no metastasis | 760 (46) |